Table 6.

The summary of the main model variables in the decision analytic model assessing the cost-effectiveness of infliximab maintenance therapy relative to conventional maintenance therapy for moderate to severe Crohn’s disease in China

Model variable	Base line value	95%CI
		Lower limit	Upper limits
Treatment efficacies of induction therapy
Disease remission rate of steroids (reference)	0.347	0.247	0.447
Disease remission rate ratio for infliximab relative to reference	1.476	0.620	2.090
Disease remission rate ratio for infliximab plus immunosuppressant relative to reference	2.331	1.639	3.315
Disease remission rate ratio for infliximab plus enteral nutrition relative to reference	1.743	1.523	2.986
Treatment efficacies of maintenance therapy
Quarterly risk of disease relapse associated with no treatment	0.207	0.146	0.284
Relative risk of disease relapse associated with infliximab relative to no treatment	0.040	0.000	0.140
Relative risk of disease relapse associated with immunosuppressant relative to no treatment	0.360	0.170	0.630
Mortality
Perioperative mortality rate associated with surgery	0.014	0.007	0.030
Hazard ratio of mortality associated with active disease relative to age and gender-matched general population	3.047	2.195	4.230
Utility ratio between CD patients and general population
Disease remission	0.829	0.622	0.994
Active disease	0.743	0.565	0.926
Direct medical costs
Annual medical costs related to disease reemission management	¥9512
Annual medical costs related to active disease management	¥14436
Surgery costs per episode	¥16781
Annual drug acquisition costs of infliximab used as induction therapy	¥49000
Drug acquisition costs of infliximab used as MT in the first year	¥39200
Drug acquisition costs of infliximab used as MT beyond the first year	¥29400

CD: Crohn’s disease; CI: Confidence interval; MT: Maintenance therapy.